Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of THR-317 in MacTel 1
NCT03669393Phase 2Completed
- Sponsor
- Oxurion
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of THR-317 in macular telangiectasia type 1, sponsored by Oxurion. Started Sep 2018; status: completed.
02
Drugs
THR-317
03
Conditions
macular telangiectasia type 1
Beyond the preview
Go deeper on NCT03669393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669393.